Physician Wealth Advisors’s Sutro Biopharma STRO Stock Holding History

Physician Wealth Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.04K	Hold	182	–	–	﹤0.01%	1022
2026 Q1	$4.53K	Hold	182	–	–	﹤0.01%	1041
2025 Q4	$2.11K	Buy	182 +52	+40%	+$493	﹤0.01%	1274
2025 Q3	$1.13K	Hold	130	–	–	﹤0.01%	1505
2025 Q2	$931	Hold	130	–	–	﹤0.01%	1480
2025 Q1	$849	Buy	+130	New	+$2.05K	﹤0.01%	1201

Other funds holding STRO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

BWL

Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Physician Wealth Advisors's STRO Position: Q2 2026 in Review

Physician Wealth Advisors held its Sutro Biopharma (STRO) position steady in Q2 2026 at 182 shares worth $6.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Physician Wealth Advisors first reported a position in STRO in Q1 2025 and has held it in 6 quarters since. 8 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Physician Wealth Advisors held 182 shares of Sutro Biopharma worth $6.04K as of Q2 2026.
Physician Wealth Advisors left its Sutro Biopharma share count unchanged in Q2 2026.
Sutro Biopharma made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1022 holding.
Physician Wealth Advisors first reported a position in Sutro Biopharma in Q1 2025 and has held it in 6 quarters since.
8 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.